Skip to main content Skip to navigation
Hamburger Menu
Search icon
Country Selector Country Selector
Luxembourg (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Products

Solutions

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      Purified Mouse Anti-Human p53
      Product Details
      Down Arrow Up Arrow


      BD Pharmingen™
      Human (QC Testing), Cow (Tested in Development)
      Mouse BALB/c IgG2a, κ
      Human p53
      Western blot (Routinely Tested), Immunohistochemistry-formalin (antigen retrieval required), Immunohistochemistry-frozen, Immunoprecipitation (Tested During Development)
      53 kDa
      0.5 mg/ml
      AB_395348
      Aqueous buffered solution containing ≤0.09% sodium azide.
      RUO


      Preparation And Storage

      The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. Store undiluted at 4°C.
      Show More blue down arrow Show Less blue up arrow

      Recommended Assay Procedures

      Applications include immunoprecipitation (1-2 µg/1x10^6 cells), western blot analysis (2 µg/ml), and immunohistochemistry of frozen and formalin-fixed paraffin-embedded tissue sections (5-20 µg/ml). Positive control cell lines include COS-7 SV40 transformed monkey kidney cells (ATCC CRL-1651), SK-BR-3 human breast carcinoma cells (ATCC HTB-30), and A431 human vulval carcinoma cells (ATCC CRL-1555). Positive immunostaining is seen in a high proportion of breast and colon carcinomas. p53 staining is not typically detected in normal skin, brain, kidney, lung, stomach or breast tissue.

      Show More blue down arrow Show Less blue up arrow

      Product Notices

      1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
      2. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
      3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
      Show More blue down arrow Show Less blue up arrow
      554293 Rev. 6
      Antibody Details
      Down Arrow Up Arrow
      DO-1

      The gene for the nuclear phosphoprotein p53 is the most commonly mutated gene yet identified in human cancers. Missense mutations occur in tumors of the colon, lung, breast, ovary, bladder and several other organs. The mutant p53 is overexpressed in a variety of transformed cells and wild-type p53 forms specific complexes with several viral oncogenes including SV40 large T, E1B from adenovirus, and E6 from human papilloma virus. Wild type p53 plays a role as a checkpoint protein for DNA damage during the G1/S-phase of the cell cycle. However, it is still unclear, whether point mutated forms of p53 are simple null mutants and/or dominant negatively acting proteins. DO-1 reacts with human wild-type and mutant p53. It cross-reacts with bovine p53 but does not cross-react with mouse or rat p53. DO-1 recognizes an epitope between amino acids 1 and 45 of all known forms of human p53. Human recombinant p53 protein was used as immunogen.

      554293 Rev. 6
      Format Details
      Down Arrow Up Arrow
      Purified
      Tissue culture supernatant is purified by either protein A/G or affinity purification methods. Both methods yield antibody in solution that is free of most other soluble proteins, lipids, etc. This format provides pure antibody that is suitable for a number of downstream applications including: secondary labeling for flow cytometry or microscopy, ELISA, Western blot, etc.
      Purified
      554293 Rev.6
      Citations & References
      Down Arrow Up Arrow
      View product citations for antibody "554293" on CiteAb

      Development References (7)

      1. Bartkova J, Bartek J, Vojtesek B, et al. Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours. Eur J Cancer. 1993; 29A(6):881-886. (Clone-specific: Immunohistochemistry). View Reference
      2. Friedrichs K, Gluba S, Eidtmann H, Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer. 1993; 72(12):3641-3647. (Clone-specific: Immunohistochemistry). View Reference
      3. Girinsky T, Koumenis C, Graeber TG, Peehl DM, Giaccia AJ. Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res. 1995; 55(17):3726-3731. (Clone-specific: Western blot). View Reference
      4. Jacquemier J, Moles JP, Penault-Llorca F, et al. p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer. 1994; 69(5):846-852. (Clone-specific: Immunohistochemistry). View Reference
      5. Vogelstein B. Cancer. A deadly inheritance. Nature. 1990; 348(6303):681-682. (Biology). View Reference
      6. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods. 1992; 151(1-2):237-244. (Clone-specific: Immunohistochemistry, Immunoprecipitation, Western blot). View Reference
      7. Xerri L, Bouabdallah R, Camerlo J, Hassoun J. Expression of the p53 gene in Hodgkin's disease: dissociation between immunohistochemistry and clinicopathological data. Hum Pathol. 1994; 25(5):449-454. (Clone-specific: Immunohistochemistry). View Reference
      View All (7) View Less
      554293 Rev. 6

       

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.